• Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and once-monthly GLP-1 receptor agonist, showing proof of concept for meaningful weight loss with low gastrointestinal side effects across obesity and type 2 diabetes populations.

• The company is now planning more than 10 Phase 3 trials for berobenatide in 2026, signaling an attempt to build a broad obesity and comorbidity franchise that could reshape Pfizer’s mix of future growth drivers.

• We’ll now examine how Pfizer’s push into once-monthly GLP-1 therapy with berobenatide may influence its longer-term investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe it can replace expiring blockbuster revenue with a new mix of oncology, vaccines and obesity drugs while supporting its sizable dividend. The berobenatide Phase 2b data and the plan for 10-plus Phase 3 obesity trials in 2026 reinforce the pipeline as the key near term catalyst, while the looming patent cliff and pressure on earnings and cash flows remain the biggest risk. On balance, this GLP‑1 update looks supportive but not transformative yet.

Among the recent announcements, the US$10.5 billion collaboration with Innovent Biologics stands out next to berobenatide. While berobenatide addresses obesity, Innovent expands Pfizer’s early stage oncology portfolio with 12 programs, including antibody drug conjugates and multi specific antibodies. Together, these moves speak directly to the core catalyst for the stock: whether new oncology and cardiometabolic assets can meaningfully offset loss of exclusivity and help sustain Pfizer’s nearly US$60 billion revenue base.

Yet beneath the promise of once monthy GLP 1 shots, investors still need to think carefully about looming patent expirations and how exposed Pfizer remains to…

Read the full narrative on Pfizer (it’s free!)

Pfizer’s narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This implies revenues will decrease by 4.6% per year and earnings will rise by about $1.7 billion from $7.5 billion today.

Uncover how Pfizer’s forecasts yield a $29.19 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this GLP 1 update, assuming Pfizer could lift earnings to about US$11.7 billion by 2029 and expand margins meaningfully, so it is worth asking whether berobenatide and the broader obesity push could eventually push the story closer to that bullish view or if the patent and pricing risks keep it closer to consensus.